2023
Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
Bewersdorf J, Shimony S, Shallis R, Liu Y, Schaefer E, Zeidan A, Goldberg A, Stein E, Marcucci G, Lindsley R, Chen E, Ramos J, Stein A, DeAngelo D, Neuberg D, Stone R, Ball B, Stahl M. Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study. Blood 2023, 142: 1589. DOI: 10.1182/blood-2023-174283.Peer-Reviewed Original ResearchIntensive induction chemotherapyAcute myeloid leukemiaComposite complete responseMedian overall survivalOverall survivalComplete responseIDH2 mutationsAllo-SCTLarge multicenter retrospective cohort studyMulticenter retrospective cohort studyAllogeneic stem cell transplantationSecondary acute myeloid leukemiaComparable overall survivalIDH1 inhibitor ivosidenibHigh rateRetrospective cohort studyStem cell transplantationLog-rank testStandard of careLarge academic centerYears of ageEffect of treatmentIDH-mutant AMLMultivariable stepwiseFit patientsPhysician responses to apple watch-detected irregular rhythm alerts
Demkowicz P, Dhruva S, Spatz E, Beatty A, Ross J, Khera R. Physician responses to apple watch-detected irregular rhythm alerts. American Heart Journal 2023, 262: 29-37. PMID: 37084933, PMCID: PMC10988207, DOI: 10.1016/j.ahj.2023.04.008.Peer-Reviewed Original ResearchConceptsAtrial fibrillationPrimary careEmergency medicinePhysician responsesDiagnostic testingUse of antiarrhythmicsClinical practice guidelinesMeasurement of BNPFurther diagnostic testingCase-based surveyLarge academic centerAF alertsAsymptomatic patientsPatient demographicsClinical symptomsTreatment optionsMedical historyPatient referralPhysician specialtyPractice guidelinesPhysician differencesRhythm monitoringAcademic centersUS FoodClinical complexitySevere Maternal Morbidity Review and Preventability Assessment in a Large Academic Center
Grechukhina O, Lipkind H, Lundsberg L, Merriam A, Raab C, Leon-Martinez D, Campbell K. Severe Maternal Morbidity Review and Preventability Assessment in a Large Academic Center. Obstetrics And Gynecology 2023, 141: 857-860. PMID: 36897178, DOI: 10.1097/aog.0000000000005116.Peer-Reviewed Original ResearchConceptsSevere maternal morbiditySystem-level factorsYale-New Haven HospitalRetrospective cohort studyHealth careDetailed case reviewLarge academic centerSMM ratesMaternal morbidityCohort studyPreventability assessmentPreventable causeSMM casesMorbidity reviewAmerican CollegeAcademic centersConsensus criteriaCase reviewPractice changeCareCauseMorbidityHemorrhagePreventabilityReview
2022
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Bakouny Z, Labaki C, Bhalla S, Schmidt A, Steinharter J, Cocco J, Tremblay D, Awad M, Kessler A, Haddad R, Evans M, Busser F, Wotman M, Curran C, Zimmerman B, Bouchard G, Jun T, Nuzzo P, Qin Q, Hirsch L, Feld J, Kelleher K, Seidman D, Huang H, Anderson-Keightly H, Zarif T, Alaiwi S, Champagne C, Rosenbloom T, Stewart P, Johnson B, Trinh Q, Tolaney S, Galsky M, Choueiri T, Doroshow D. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Annals Of Oncology 2022, 33: 836-844. PMID: 35715285, PMCID: PMC9197329, DOI: 10.1016/j.annonc.2022.04.071.Peer-Reviewed Original ResearchConceptsTherapeutic clinical trialsClinical trialsPatient accrualCancer Outcomes StudyNon-white patientsOncological clinical trialsLarge academic centerEarly pandemic periodClinical trial activityCOVID-19Clinical trial conductMulticenter studyNew patientsOncological trialsDirect infectionOutcome studiesPatientsAcademic centersTrial activationTrial conductNormal levelsCohortProgressive recoveryTrialsRacial disparities
2020
Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes
Bewersdorf JP, Zeidan AM. Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes. Cancer 2020, 126: 4664-4667. PMID: 32767670, DOI: 10.1002/cncr.33106.Peer-Reviewed Original Research
2019
Pulmonary Arterial Elastance and INTERMACS-Defined Right Heart Failure Following Left Ventricular Assist Device
Muslem R, Ong C, Tomashitis B, Schultz J, Ramu B, Craig M, Van Bakel A, Gilotra N, Sharma K, Hsu S, Whitman G, Leary P, Cogswell R, Lozonschi L, Houston B, Zijlstra F, Caliskan K, Bogers A, Tedford R. Pulmonary Arterial Elastance and INTERMACS-Defined Right Heart Failure Following Left Ventricular Assist Device. Circulation Heart Failure 2019, 12: e005923. PMID: 31401840, DOI: 10.1161/circheartfailure.119.005923.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCardiac CatheterizationEchocardiographyElasticityFemaleHeart FailureHeart VentriclesHeart-Assist DevicesHumansMaleMiddle AgedPostoperative ComplicationsPulmonary ArteryRegistriesRetrospective StudiesStroke VolumeSurvival RateUnited StatesVascular ResistanceVentricular Function, RightConceptsSevere acute right heart failureAcute right heart failureRight heart failureSystolic pulmonary artery pressurePulmonary artery pressureVentricular assist device implantationPulmonary arterial elastanceAssist device implantationRight atrial pressureArtery pressureVentricular assist deviceAtrial pressureHeart failureArterial elastanceDevice implantationAssist deviceSevere right heart failureIndependent hazard ratioStrongest hemodynamic predictorRight heart catheterizationLarge academic centerDevice survival ratesPreimplant variablesCause mortalityHeart catheterization
2018
The Value of Negative Diagnosis in Thyroid Fine-Needle Aspiration: a Retrospective Study with Histologic Follow-Up
Abi-Raad R, Prasad M, Baldassari R, Schofield K, Callender GG, Chhieng D, Adeniran AJ. The Value of Negative Diagnosis in Thyroid Fine-Needle Aspiration: a Retrospective Study with Histologic Follow-Up. Endocrine Pathology 2018, 29: 269-275. PMID: 29949024, DOI: 10.1007/s12022-018-9536-5.Peer-Reviewed Original ResearchConceptsFine-needle aspirationThyroid fine-needle aspirationFalse negative rateBenign diagnosisFNA diagnosisIncidence of malignancySubsequent surgical resectionCategory of patientsPapillary-like nuclear featuresNoninvasive follicular thyroid neoplasmLarge academic centerPapillary thyroid carcinomaThyroid FNA resultsFalse-negative casesFollicular thyroid neoplasmSurgical resectionRetrospective reviewBenign goiterInadequate biopsiesLymphocytic thyroiditisNeoplastic casesRetrospective studyTumor sizeNIFTP casesSurgical follow
2017
Hard-wiring survivorship care plan delivery.
Barbarotta L, Jauk M, Chiang A, Sanft T. Hard-wiring survivorship care plan delivery. Journal Of Clinical Oncology 2017, 35: 113-113. DOI: 10.1200/jco.2017.35.8_suppl.113.Peer-Reviewed Original ResearchElectronic medical recordsCare plansEligible patientsSurvivorship careCancer HospitalNCI-designated Comprehensive Cancer CenterCare plan creationLarge cancer hospitalSmilow Cancer HospitalSurvivorship care planningQuality cancer careComprehensive cancer centerComprehensive survivorship careModel of careLarge academic centerCommon cancer typesHigh-quality patient careQuality patient careSCP deliveryCancer CenterStandard operating proceduresCancer careSingle institutionCancer programsMedical records
2015
HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era
Grew D, Bitterman D, Leichman CG, Leichman L, Sanfilippo N, Moore HG, Du K. HIV Infection Is Associated With Poor Outcomes for Patients With Anal Cancer in the Highly Active Antiretroviral Therapy Era. Diseases Of The Colon & Rectum 2015, 58: 1130-1136. PMID: 26544809, DOI: 10.1097/dcr.0000000000000476.Peer-Reviewed Original ResearchConceptsHIV-negative patientsHIV-positive patientsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraColostomy-free survivalOverall survival rateAnal cancerSurvival rateTherapy eraMultivariate analysisColostomy-free survival ratesLocal recurrence-free survivalDistant metastasis-free survivalRetrospective chart reviewSmall patient numbersRecurrence-free survivalMetastasis-free survivalOutpatient oncology clinicsLarge academic centerDefinitive chemoradiationDefinitive chemoradiotherapyChart reviewOverall survivalPatient characteristicsHIV infectionIdentification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials
Baggs J, Yousey-Hindes K, Ashley ED, Meek J, Dumyati G, Cohen J, Wise ME, McDonald LC, Lessa FC. Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. Vaccine 2015, 33: 6241-6249. PMID: 26450660, PMCID: PMC4702247, DOI: 10.1016/j.vaccine.2015.09.078.Peer-Reviewed Original ResearchConceptsEmerging Infections ProgramHigh-risk groupRisk groupsRisk scoreIndex hospitalizationHospital dischargeDerivation cohortVaccine trialsValidation cohortDifficile infectionCox proportional hazards modelRisk of CDIAcute care hospitalizationIdentification of patientsClostridium difficile infectionHospital discharge dataNumber of hospitalizationsLow-risk groupProportional hazards modelLarge academic centerAdmission diagnosisPrimary outcomeInpatient stayPatient populationPharmacy data
2014
Emergency department (ED) utilization and hospital admission rates among oncology patients at a large academic center and the need for improved urgent care access.
Adelson K, Dest V, Velji S, Lisitano R, Lilenbaum R. Emergency department (ED) utilization and hospital admission rates among oncology patients at a large academic center and the need for improved urgent care access. Journal Of Clinical Oncology 2014, 32: 19-19. DOI: 10.1200/jco.2014.32.30_suppl.19.Peer-Reviewed Original ResearchOncology patientsHospital admissionSmilow Cancer HospitalYale-New HavenPalliative care consultationHospital admission ratesEmergency department utilizationLarge academic centerEpic electronic medical recordAmbulatory oncology practicesElectronic medical recordsAverage daily costEducation of physiciansCancer expendituresMean hospitalizationAbdominal painED referralsAdvanced cancerCancer HospitalHospital EDUrgent presentationCare consultationsMost hospitalizationsDisease groupAdmission rates
2013
Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
Buza N, English DP, Santin AD, Hui P. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology 2013, 26: 1605-1612. PMID: 23765245, DOI: 10.1038/modpathol.2013.113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaSerous carcinomaHER2 overexpressionEndometrial carcinomaMedical recordsImmunohistochemical scoreHER2 testingProtein expressionHER2 immunohistochemistrySignificant heterogeneityScoring systemMultiple tumor sectionsPure serous carcinomaHER2-positive casesHER2-positive tumorsScoring criteriaEndometrial carcinoma casesFDA criteriaPatients' medical recordsLarge academic centerHER2 FISH resultsHER2 protein overexpressionPromising therapeutic targetOverall concordance rateHER2 immunohistochemical scores
2006
Facing the Malpractice Crisis: Academic Physicians’ Willingness to Accept Quick Fix Solutions
Levine RB, Kravet SJ, Reed DA, Windish DM, Wolfe L, Wright SM. Facing the Malpractice Crisis: Academic Physicians’ Willingness to Accept Quick Fix Solutions. Southern Medical Journal 2006, 99: 1334-1336. PMID: 17233189, DOI: 10.1097/01.smj.0000235483.54376.18.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply